{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05965700",
            "orgStudyIdInfo": {
                "id": "NVG-291-201"
            },
            "organization": {
                "fullName": "NervGen Pharma",
                "class": "INDUSTRY"
            },
            "briefTitle": "NVG-291 in Spinal Cord Injury Subjects",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "nvg-in-spinal-cord-injury-subjects"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-16",
            "studyFirstSubmitQcDate": "2023-07-25",
            "studyFirstPostDateStruct": {
                "date": "2023-07-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NervGen Pharma",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Single site (Shirley Ryan AbilityLab) Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects",
            "detailedDescription": "To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures."
        },
        "conditionsModule": {
            "conditions": [
                "Spinal Cord Injuries",
                "Chronic Spinal Cord Injury",
                "Subacute Spinal Cord Injury"
            ],
            "keywords": [
                "Spinal Cord Injury"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Randomized, Double-Blind, Placebo-Controlled",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NVG-291 for Injection",
                    "type": "EXPERIMENTAL",
                    "description": "Injected under the skin (subcutaneous).",
                    "interventionNames": [
                        "Drug: NVG-291"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Injected under the skin (subcutaneous).",
                    "interventionNames": [
                        "Drug: NVG-291"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NVG-291",
                    "description": "A once daily injection",
                    "armGroupLabels": [
                        "NVG-291 for Injection",
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Electrophysiological",
                    "description": "MEP amplitudes (corticospinal contribution)",
                    "timeFrame": "16 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "10mWT time",
                    "description": "Walking speed",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "9-HPT time",
                    "description": "Upper extremity dexterity",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Pinch dynamometry",
                    "description": "Recorded force",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Graded and Redefined Assessment of Strength, Sensibility, and Prehension Test",
                    "description": "Hand function Max Score 116 points (higher is better)",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Lower extremity motor score (LEMS)",
                    "description": "Lower extremity Max Score 50 points (25 points per side - higher is better)",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Upper extremity motor score (UEMS)",
                    "description": "Upper extremity Max Score 50 points (25 points per side - higher is better)",
                    "timeFrame": "16 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nA subject must provide written informed consent in accordance with local regulations prior to initiation of any study-specific activities/procedures. A legally authorized representative (LAR) may be used to assist in signing the informed consent.\n\nCervical SCI resulting from acute physical trauma.\n\nMales and females\n\nAge 18 - 75 years, inclusive.\n\nCervical SCI, incomplete, with a neurological level of injury being at C7 or higher.\n\nHad incomplete cervical SCI within the period from 1 year to 10 years inclusive (Chronic cohort 1) OR within 10 days to 49 days inclusive (Subacute cohort 2) at time of randomization.\n\nMust be able to volitionally initiate at least one step on one leg (without body weight support).\n\nMust have a Walking Index for Spinal Cord Injury II (WISCI II) score as follows:\n\n1. For Chronic cohort 1: Less than or equal to Level 14.\n2. For Subacute cohort 2: Less than or equal to Level 8.\n\nGRASSP Prehension Ability score\n\nFor Chronic cohort 1:\n\ni. Must have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity. ii. Must have no more than one Prehension Ability grasp patterns score = 4 in the upper extremity satisfying criterion i\n\nFor Subacute cohort 2:\n\ni. Must have a score of 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity. ii. Must have no more than one Prehension Ability grasp patterns score = 3 in the upper extremity satisfying criterion i. iii. Must not have a Prehension Ability grasp patterns score = 4 in the upper extremity satisfying criterion i.\n\nMust be fluent in English.\n\nSubjects must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.\n\nExclusion Criteria:\n\nNontraumatic SCI (e.g., due to infection, ischemia, metabolic abnormality, congenital abnormality, malignancy, radiation injury, or other disease process).\n\nSpinal cord injury due to gunshot wound or penetrating injury.\n\nTwo or more (noncontiguous) spinal cord lesions.\n\nMRI evidence of anatomically complete spinal cord transection.\n\nAny form of ventilatory dependence.\n\nAny condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, amputation.\n\nHistory of seizures (febrile seizures allowed).\n\nMetal implant in the head.\n\nHistory of traumatic brain injury without recovery.\n\nAny neurological condition that may interfere with performance or confound assessment, such as multiple sclerosis, stroke, or syringomyelia.\n\nHistory of substance abuse within 12 months prior to screening, based on medical records or self-report.\n\nEvidence of spinal instability or persistent spinal stenosis and/or compression related to initial trauma.\n\nPrior treatment with cell therapy delivered into the CNS (intrathecal or intraparenchymal).\n\nSevere neuropathic pain inadequately controlled by medication.\n\nBody mass index (BMI) \\> 40 (body weight in kilograms divided by height in meters squared).\n\nReceived botulinum toxin injection(s) in an upper or lower extremity muscle in the prior 6 months.\n\nReceived 4-aminopyridine within 14 days of screening.\n\nPrior treatment with a protein tyrosine phosphatase sigma (PTP\u03c3) mimetic peptide.\n\nIntrathecal opioid use.\n\nCurrently participating in an interventional clinical trial.\n\nReceived a non-permitted medication within 5.5 half-lives or 7 days, whichever is longer, prior to randomization\n\nReceiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent to participate in this study or within 4 weeks of randomization, whichever is longer.\n\nAny implanted internal spinal cord stimulator.\n\nCurrently receiving neuromuscular stimulation.\n\nCurrently receiving vagal nerve stimulation.\n\nAny contraindication to undergo MRI studies such as:\n\n1. History of a cardiac pacemaker or pacemaker wires, OR\n2. Metallic particles in the body, OR\n3. Baclofen pump, OR\n4. Vascular clips in the head, OR\n5. Prosthetic heart valves, OR\n6. Severe claustrophobia impeding ability to participate in an imaging study.\n\nMalignancy within 5 years prior to screening, except for non-melanoma skin cancers or cervical or breast ductal carcinoma in situ.\n\nSevere renal insufficiency, as defined by eGFR \\< 30 mL/min/1.73m2.\n\nAny other social or medical condition (e.g., uncontrolled diabetes, unstable hypertension) which, in the opinion of the investigator, would make the subject unsuitable for study participation.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Connor Ott",
                    "role": "CONTACT",
                    "phone": "(855) 559-6902",
                    "email": "cott@sralab.org"
                },
                {
                    "name": "Paragon Global CRS",
                    "role": "CONTACT",
                    "phone": "(855) 559-6902",
                    "email": "NVG-291@paragonglobalcrs.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Daniel Mikol, M.D. Ph.D.",
                    "affiliation": "NervGen Pharma",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Shirley Ryan AbilityLab",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Paragon Global CRS",
                            "role": "CONTACT",
                            "phone": "855-559-6902",
                            "email": "NVG-291@paragonglobalcrs.com"
                        },
                        {
                            "name": "Connor Ott",
                            "role": "CONTACT",
                            "phone": "1-312-238-7347",
                            "email": "cott@sralab.org"
                        },
                        {
                            "name": "Monica A Perez, PT, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "David Chen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013119",
                    "term": "Spinal Cord Injuries"
                },
                {
                    "id": "D000014947",
                    "term": "Wounds and Injuries"
                }
            ],
            "ancestors": [
                {
                    "id": "D000013118",
                    "term": "Spinal Cord Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000020196",
                    "term": "Trauma, Nervous System"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15916",
                    "name": "Spinal Cord Injuries",
                    "asFound": "Spinal Cord Injury",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "asFound": "Injury",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15915",
                    "name": "Spinal Cord Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22023",
                    "name": "Trauma, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}